After surgery , women received three cycles of FEC ( fluorouracil 500 mg/m ( 2 ) plus epirubicin 100 mg/m ( 2 ) plus cyclophosphamide 500 mg/m ( 2 ) ) given intravenously every 3 weeks , followed by 34 weeks of the same assigned neoadjuvant anti-HER2 therapy .